drugset / Trial / NCT03894579
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.
Timeline
- Start
- 2019-07-18
- Primary completion
- 2019-12-03
- Completion
- 2019-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | 1e+09 cells | Intravenous |
| Subject | TROCULEUCEL | Cell therapy | 2e+09 cells | Intravenous |
| Subject | TROCULEUCEL | Cell therapy | 4e+09 cells | Intravenous |